Reportlinker Adds Small Molecule Kinase Inhibit...(I-39 3. KINASE INHIBITORS: A RU...)

3. KINASE INHIBITORS: A RUDIMENTARY OVERVIEW II-40

Kinase Inhibitors: A Definition II-40

Kinase Inhibitors Vs Monoclonal Antibodies (mAbs): A Comparison II-40

Comparison of Various Pharmacological and Pharmacokinetic

Parameters For Small Molecules and Monoclonal Antibodies II-41

Types of Protein Kinase Inhibitors: A Classification II-41

Receptor Tyrosine Kinase (RTK) Inhibitors II-42

EGFR (Epidermal Growth Factor Receptor) Inhibitors II-42

HER2 Inhibitors II-42

VEGF (Vascular Endothelial Growth Factor) Inhibitors II-42

FLT3 (Fms-like tyrosine kinase 3) Inhibitors II-43

Non- Receptor Tyrosine Kinase Inhibitors II-43

BCR-Abl Kinase Inhibitors II-43

Src Kinase Inhibitors II-43

Janus (JAK) Kinase Inhibitors II-44

Serine-Threonine Kinase Inhibitors II-44

mTOR (Mammalian Target of Rapamycin) Inhibitors II-44

Rho Kinase Inhibitors II-44

CDK (Cyclin Dependent Kinase) Inhibitors II-45

Protein Kinase C (PKC) InhibitorsII-45

PI3K (Phosphatidylinositol-3-Kinase) Inhibitors II-45

Aurora Kinase Inhibitors II-45

MAP (Mitogen activated protein) / MEK Inhibitors II-46

JNK (C-JUN N-TERMINAL KINASE) INHIBITORS II-46

Others II-46

4. PRODUCT LAUNCHES II-47

KAI Initiates Third Phase Iia Trial for KAI-1678 II-47

SuperGen Discovers a New Class of Kinase Inhibitors II-47

AVEO Joins Hands with Biogen to Develop and Market ErbB3-

Targeted AntibodiesII-47

AVEO Identifies New Indication for AV-951 Triple VEGF

Receptor Inhibitor II-48

GPC Biotech Demonstrates Role of Kinase Inhibitor in Multiple Myeloma Treatment II-48

MD Biosciences and PharmaGap Join Hands II-48

New JAK Inhibitor Drug from Pfizer Enters Phase III Trial II-48

Millennium Commences Phase II Trials for MLN8237 II-49